Renovaro Biosciences Inc

Renovaro Biosciences (RENB) Stock

Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Renovaro Biosciences in May 2026.

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Stock Performance Snapshot

Below Average

Financial Health

Renovaro Biosciences Inc has low book value per share and no cash flow, raising concerns.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring RENB

Alternative Cancer Therapies Focus Shifts 2025

Alternative Cancer Therapies Focus Shifts 2025

The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.

Published: October 13, 2025

Explore Basket
New Moon Portfolio

New Moon Portfolio

This collection represents the very beginning of the next technological cycle. These carefully selected companies are sowing the seeds of future industries, giving you early exposure to disruptive innovators poised for exponential growth as their technologies reshape our world.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

Why invest with Nemo?

Nemo Logo Fade
πŸ†“

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

πŸ”’

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

πŸ’°

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions